OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Computing brain metastasis impact	723
Fructose takes a detour to feed cancer	694
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	498
Combinatorial strategies to target RAS-driven cancers	494
Implementing practice-changing progress for managing cancer of unknown primary	476
Emerging strategies to investigate the biology of early cancer	437
Claudin proteins as emerging therapeutic targets for solid tumours	386
Oncofetal reprogramming in tumour development and progression	378
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	327
INVADEseq to study the intratumoural microbiota at host single-cell resolution	318
Exploiting metabolic cell death for cancer therapy	305
Mapping the prostate cell family tree	301
Fighting cancer with fat	292
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	280
The recruitment of metastasis-associated monocytes	269
3D chromatin architecture as a predictor of somatic mutations in cancer genomes	268
Connie J. Eaves (1944–2024)	264
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	261
Translating premalignant biology to accelerate non-small-cell lung cancer interception	255
Avoiding cancer through collective behaviour	254
The evolution of cancer and ageing: a history of constraint	229
Tertiary lymphoid structures as hubs of antitumour immunity	225
How medical anthropology can contribute to cancer research	223
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	221
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	215

Epithelial and stromal co-evolution and complicity in pancreatic cancer	206
Nanoreceptors take down mutant p53	205
Impersonating neurons	201
Tumour EVPs disrupt liver function	196
AACR 2025	194
Measuring HLA disruption using MHC Hammer	192
Gut microbes produce novel genotoxic metabolites	187
Persistence is key	186
Thelpers? More like Ttroublemakers	186
Dendritic cells rise and shine	182
Removing barriers to address sex differences in anticancer drug toxicity	175
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	172
How chemokines organize the tumour microenvironment	168
No mutation, tumour initiation	162
Defining a ‘cells to society’ research framework for appendiceal tumours	161
Rethinking ovarian cancer III: the past decade and future directions	159
Natural killer cells in antitumour adoptive cell immunotherapy	157
3D bioprinted cancer models: from basic biology to drug development	153
Bone voyage: immune crosstalk sets sail	145
B-ring sterols to the rescue	140
Visualizing intratumoural heterogeneity with EpicMIBI	139
Double trouble for the tumour glycocode	133
Identifying spatial cellular structures with SPACE-GM	132
In-depth organoid profiling of pancreatic cancer	125
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	124
Context-dependent synthetic lethality — an emerging precision therapeutic approach	122
Leveraging the replication stress response to optimize cancer therapy	114
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	114
Opportunities and challenges of targeting cGAS–STING in cancer	112
The immune microenvironment of colorectal cancer	105
The path to leptomeningeal metastasis	105
Linking cell mechanical memory and cancer metastasis	103
Enhancer and metabolic rewiring by KMT2C–COMPASS or KMT2D–COMPASS family loss in cancer creates druggable vulnerabilities	101
Regulatory T cells in the tumour microenvironment	101
Dynamics and specificities of T cells in cancer immunotherapy	97
Encoding spatial tumour dynamics with Starfysh	95
Understanding and addressing race disparities in childhood cancer outcomes	95
Race influences the tumour microbiome	95
Deciphering the cancer genome and epigenome	93
ER stress sparks nerve pain	85
The link between vitamin D and prostate cancer	83
Being in the zone	83
Re-routing IgE for cancer therapy	80
Stem cells as an essential mediator of the exercise–tumorigenesis link	77
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research	74
Polygenic scores in cancer	71
RNA splicing dysregulation and the hallmarks of cancer	70
Beat it!	70
Targeted protein degradation for cancer therapy	69
Detection of cytokine-responsive cells using CyCLoPs	68

Cancer nanomedicine	68
Acetyl-CoA metabolism in cancer	67
Z-nucleic acids give immunotherapy a boost	66
Local CAR manufacturing	64
Prime editing GEMMs to model cancer mutations	64
Tamoxifen takes the wheel	64
Integrative medicine in oncology: redefining the standard of care	62
When the time is right	62
Right ON target: a new RAS-GTP inhibitor	61
NOTUM-mediated stem cell competition in CRC	60
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	60
Expanding the utility of precision oncology knowledge bases	60
Chromothripsis in cancer	56
Decoding cancer across scales with metabolomics	55
Tertiary lymphoid structures in anticancer immunity	55
Defining precancer: a grand challenge for the cancer community	55
In vivo labelling system to study cell neighbourhoods	53
Revealing genomic secrets of archival FFPE samples	52
Judith Campisi (1948–2024)	52
New pathogen on the block	51
Inferring cancer metabolism from gene-expression data	49
Melanomagenesis antagonizes stem cell ageing	48
N6-Methyladenosine: an RNA modification as a central regulator of cancer	47
Regulation of immune checkpoint molecules in cancer immune evasion and therapy	46
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	42
The present and future of the Cancer Dependency Map	41
Recent advances in therapeutic cancer vaccines	39
Cancer risk in children with congenital anomalies	39
Carcinogenesis at single-cell resolution	38
Global post-mortem tissue donation programmes to accelerate cancer research	38
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy	38
Transfer RNAs as dynamic and critical regulators of cancer progression	38
Patient-derived organoids unveil sarcoma vulnerabilities	37
Epigenomic heterogeneity as a source of tumour evolution	36
Focusing on the complex and dynamic interplay between ageing and cancer	36
A timeline of tumour-associated macrophage biology	36
Traject3d for studying 3D cellular heterogeneity	34
Digitally enhanced Raman spectroscopy	33
Author Correction: Integrative medicine in oncology: redefining the standard of care	32
Targeting cancer cell dormancy	31
Fcγ receptors and immunomodulatory antibodies in cancer	31